Accustem Sciences Inc
accustem.comWhat Do They Do?
Develops genomic cancer tests, including a blood test to assess lung nodules and a breast cancer test to estimate recurrence risk, for patients and their physicians.
10-K for FY2025, filed Apr 14, 2026We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who…View ↗
The MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by LDCT (low dose computer…View ↗
StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (“DR”) in luminal (ER+/HER2-negative) breast…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Apr 14, 2026
Who Are Their Customers?
The company is developing tests for patients with lung nodules and early-stage breast cancer, with testing planned through a partner laboratory and sales initially focused on a small number of early-adopting sites.
10-K for FY2025, filed Apr 14, 2026We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who…View ↗
In order to commercialize a proprietary genomic classifier, it must meet two important benchmarks- the test must have sufficient data to be…View ↗
Our revenue is expected to be derived from different sources including standard private third-party and government medical insurance…View ↗
How Are They Changing?
Added a lung nodule test
The latest report centers on MSC for lung nodules alongside StemPrintER for early-stage breast cancer; the older report focused on StemPrintER and described rights to the MSC test.
10-K for FY2022, filed Feb 15, 2023 10-K for FY2025, filed Apr 14, 2026We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who…View ↗
Who Do They Compete With?
Competes with Biodesix, Veracyte, Hologic, Eurobio Scientific, Agendia, Exact Sciences, Ambry, Color Health, Foundation Medicine, Guardant, Invitae, Laboratory Corporation of America, Natera, Neogenomics, Quest Diagnostics, and Tempus
10-K for FY2025, filed Apr 14, 2026Nodify Lung (Biodesix) consists of two blood-based proteomic tests, the Nodify CDT® & Nodify XL2® tests to help providers decipher the risk…View ↗
Loading...
